Choi Changhoon, Cho Yeonwoo, Son Arang, Shin Sung-Won, Lee Yeon-Ju, Park Hee Chul
Department of Radiation Oncology, Samsung Medical Center, Seoul 06351, Korea.
Marine Natural Products Chemistry Laboratory, Korea Institute of Ocean Science and Technology, 385 Haeyangro, Busan 49111, Korea.
Mar Drugs. 2020 Sep 29;18(10):500. doi: 10.3390/md18100500.
Radiation therapy (RT) is an effective local treatment for unresectable hepatocellular carcinoma (HCC), but there are currently no predictive biomarkers to guide treatment decision for RT or adjuvant systemic drugs to be combined with RT for HCC patients. Previously, we reported that extracts of the marine sponge sp. may contain a natural radiosensitizer for HCC treatment. In this study, we isolated (-)-agelamide D from extract and investigated the mechanism underlying its radiosensitization. (-)-Agelamide D enhanced radiation sensitivity of Hep3B cells with decreased clonogenic survival and increased apoptotic cell death. Furthermore, (-)-agelamide D increased the expression of protein kinase RNA-like endoplasmic reticulum kinase/inositol-requiring enzyme 1α/activating transcription factor 4 (PERK/eIF2α/ATF4), a key pathway of the unfolded protein response (UPR) in multiple HCC cell lines, and augmented radiation-induced UPR signaling. In vivo xenograft experiments confirmed that (-)-agelamide D enhanced tumor growth inhibition by radiation without systemic toxicity. Immunohistochemistry results showed that (-)-agelamide D further increased radiation-induced ATF4 expression and apoptotic cell death, which was consistent with our in vitro finding. Collectively, our results provide preclinical evidence that the use of UPR inducers such as (-)-agelamide D may enhance the efficacy of RT in HCC management.
放射治疗(RT)是不可切除肝细胞癌(HCC)的一种有效局部治疗方法,但目前尚无预测生物标志物来指导RT的治疗决策,也没有用于HCC患者与RT联合使用的辅助性全身药物。此前,我们报道海洋海绵提取物可能含有用于HCC治疗的天然放射增敏剂。在本研究中,我们从提取物中分离出(-)-agelamide D,并研究了其放射增敏作用的潜在机制。(-)-agelamide D增强了Hep3B细胞的辐射敏感性,克隆形成存活率降低,凋亡细胞死亡增加。此外,(-)-agelamide D增加了蛋白激酶RNA样内质网激酶/肌醇需求酶1α/激活转录因子4(PERK/eIF2α/ATF4)的表达,这是多种HCC细胞系中未折叠蛋白反应(UPR)的关键途径,并增强了辐射诱导的UPR信号传导。体内异种移植实验证实,(-)-agelamide D增强了辐射对肿瘤生长的抑制作用,且无全身毒性。免疫组织化学结果表明,(-)-agelamide D进一步增加了辐射诱导的ATF4表达和凋亡细胞死亡,这与我们的体外研究结果一致。总体而言,我们的结果提供了临床前证据,表明使用(-)-agelamide D等UPR诱导剂可能会提高RT在HCC治疗中的疗效。